このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

再発・難治性多発性骨髄腫患者におけるIASO206

再発・難治性多発性骨髄腫患者におけるIASO206の安全性と有効性に関する探索的研究

This study is an open-label, single-arm early exploratory clinical study, aiming to evaluate the safety, tolerability and preliminary efficacy of IASO206 Injection(In Vivo CAR-T) in Patients with Relapsed/Refractory Multiple Myeloma

調査の概要

状態

募集

条件

介入・治療

研究の種類

介入

入学 (推定)

18

段階

  • 初期フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Tianjin、中国
        • 募集
        • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
        • コンタクト:
        • 主任研究者:
          • gang An

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~75年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • 18 to 75 years old, male or female;

  • Diagnosed with relapsed/refractory multiple myeloma (RRMM) according to IMWG criteria, and have received at least 2 lines of treatment including one proteasome inhibitor and one immunomodulator; with documented disease progression (based on examination data) during or within 12 months after the latest anti-myeloma treatment (subjects whose last-line treatment was CAR-T therapy are not required to have progression within 12 months);

  • Presence of measurable lesions during screening according to any of the following criteria:

    • Serum monoclonal protein (M-protein) level: ≥5 g/L f;
    • Urine M protein level ≥200 mg/24 hours;
    • Light chain multiple myeloma without measurable lesions in serum or urine: the affected serum free light chain ≥100 mg/L with abnormal serum κ/λ free light chain ratio;
  • BCMA expression on MM cells determined by flow cytometry or pathology immunohistochemistry;

  • ECOG score ≤ 2;

  • Expected survival time ≥12 weeks;

  • Subjects must have adequate organ function:

  • Hematology: Absolute neutrophil count (ANC) ≥ 1×10^9/L (supportive treatment within 7 days before laboratory test is not allowed); Absolute lymphocyte count (ALC) )≥0.3×10^9/L; platelets≥50×10^9/L (blood transfusion support within 7 days before laboratory test is not allowed); hemoglobin ≥60 g/L (without red blood cell [RBC] transfusion within 7 days before laboratory test);

    • Liver function: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)≤1.5×upper limit of normal (ULN); serum total bilirubin≤1.5×ULN;
    • Renal function: creatinine clearance calculated according to Cockcroft-Gault formula≥ 40 ml/min.
    • Coagulation function: fibrinogen ≥1.0 g/L; activated partial thromboplastin time≤1.5×ULN, prothrombin time (PT)≤1.5×ULN;
    • Blood oxygen saturation>91%;
    • Left ventricular ejection fraction (LVEF) ≥50%;
  • Subjects and their spouses agree to use effective contraceptive methods with tools or drugs from the time the subject signs the informed consent form until one year after administration;

  • Subjects must sign a written informed consent form approved by the ethics committee before initiating the screening process.

Exclusion Criteria:

  • Patients with suspected or confirmed central nervous system involvement by plasma cell neoplasms;

  • Multiple myeloma patients with plasma cell leukemia;

  • Patients with amyloidosis;

  • Patients who have received autologous hematopoietic stem cell transplantation (Auto-HSCT) within 12 weeks before enrollment, or have a history of allogeneic hematopoietic stem cell transplantation (Allo-HSCT);

  • Patients who have received previous BCMA-targeted therapy;

  • Patients who have received plasma cell-targeted cellular therapy within 3 months before the screening period, or in whom received cellular therapy products can still be detected in peripheral blood;

  • Patients who have received other anti-tumor treatments requires an appropriate washout period:

    • Received Bendamustine, fludalabine or high-dose cyclophosphoyl within 9 months before enrollment,or;
    • Received Monoclonal antibody treatment for multiple myeloma within 21 days before enrollment, or;
    • Received cytotoxic chemotherapy or proteasome inhibitor treatment within 14 days before enrollment, or;
    • Received immunomodulatory treatment within 7 days before enrollment, or;
    • Received other anti-tumor treatments (including but not limited to experimental drugs) listed above within 14 days before enrollment or at least 5 half-lives (whichever is longer);
  • Patients requiring long-term use of therapeutic doses of corticosteroids during the study period (defined as prednisone or equivalent >20 mg/day), except for physiological replacement, topical, and inhaled use;

  • Severe heart diseases:including but not limited to unstable angina, myocardial infarction (within 6 months before screening), congestive heart failure (New York Heart Association [NYHA] classification ≥ grade III), severe arrhythmia,hypertension that cannot be controlled by medication;

  • Unstable systemic diseases judged by the investigator: including but not limited to severe liver, kidney or metabolic diseases;

  • Patient who needs chronic use of immunosuppressive agents;

  • Patients with malignant tumors other than multiple myeloma within 5 years before screening, excluding fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical resection, and those after radical resection Ductal carcinoma in situ of breast and papillary thyroid carcinoma;

  • Patients with a history of solid organ transplantation;

  • Major surgery history within 2 weeks before entering the study, or scheduled surgery during the study period or within 2 weeks after the study treatment;

  • Serious uncontrolled infections during screening: Bacterial, viral, fungal, etc. infections;

  • Positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) and detectable hepatitis B virus (HBV) DNA in peripheral blood; hepatitis C virus (HCV) antibody positive and peripheral blood hepatitis C virus ( HCV) RNA positive; human immunodeficiency virus (HIV) antibody positive; cytomegalovirus (CMV) DNA test positive; syphilis test positive;

  • Patients who have received inactivated vaccines within 4 weeks before enrollment;

  • Women who are pregnant or breastfeeding;

  • Patients with mental illness, consciousness disorder, or central nervous system diseases, including but not limited to epilepsy or a history of Parkinson's disease;

  • Known severe allergic reaction to IASO206 or its formulation components (such as tocilizumab);

  • Patients with unresolved non-hematological toxic reactions from previous treatments, which have not returned to baseline or ≤Grade 1 (except for alopecia and Grade 2 peripheral neuropathy);

  • Other situations considered unsuitable by the investigator.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
アクティブコンパレータ:IASO206

IASO206 will be administered in one infusion.

The third-generation self-inactivating lentiviral vector that carries a BCMA-targeted CAR.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
The incidence and severity of adverse events(AEs)
時間枠:up to 2 years after IASO206 infusion

Cytokine release syndrome (CRS) and ICANS would be graded according to the ASTCT consensus.

All other AEs would be assessed according to the Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0).

up to 2 years after IASO206 infusion

二次結果の測定

結果測定
メジャーの説明
時間枠
Overall response rate (ORR)
時間枠:up to 2 years after IASO206 infusion

The proportions of subjects achieving stringent Complete Response (sCR), Complete Response (CR), Very Good Partial Response (VGPR), and Partial Response (PR) after IASO206 infusion.

up to 2 years after IASO206 infusion
Time to response (TTR)
時間枠:up to 2 years after IASO206 infusion

The time from the start of the drug infusion in subjects to the first occurrence of sCR, CR, VGPR, or PR.

up to 2 years after IASO206 infusion
MRD negativity rate
時間枠:up to 2 years after IASO206 infusion

The proportion of subjects who achieve MRD-negativity after IASO206 infusion.

up to 2 years after IASO206 infusion
Duration of response (DOR)
時間枠:up to 2 years after IASO206 infusion

The time from the first assessment of sCR or CR or VGPR or PR to the first assessment of disease progression or death from any cause.

up to 2 years after IASO206 infusion
Progression-free survival (PFS)
時間枠:up to 2 years after IASO206 infusion

The time from the date IASO206 infusion to the date of first disease progression or death from any cause (whichever occurs first)

up to 2 years after IASO206 infusion
Overall survival (OS)
時間枠:up to 2 years after IASO206 infusion

The time from the date of IASO206 infusion to the date of death from any reason.

up to 2 years after IASO206 infusion
Pharmacodynamics(PD)
時間枠:up to 2 years after IASO206 infusion

The levels of cytokines (IL-6, serum ferritin, CRP) in peripheral blood at each time point,and lymphocyte subsets after IASO206 infusion.

up to 2 years after IASO206 infusion
Pharmacokinetic Analysis(PK)
時間枠:up to 24 month after IASO206 infusion

Maximum concentration (Cmax) of IASO206 particle and CAR-T cells.

up to 24 month after IASO206 infusion
Pharmacokinetic Analysis(PK)
時間枠:up to 24 month after IASO206 infusion

Time of maximum concentration (Tmax) of IASO206 particle and CAR-T cells.

up to 24 month after IASO206 infusion
Pharmacokinetic Analysis(PK)
時間枠:up to 24 month after IASO206 infusion

Area under the concentration versus time curve: IASO206 particle AUC0-12d; CAR-T cell AUC0-28d,AUC0-90d,AUC0-180d,AUC0-last

up to 24 month after IASO206 infusion

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年1月8日

一次修了 (推定)

2026年12月15日

研究の完了 (推定)

2028年10月15日

試験登録日

最初に提出

2025年12月9日

QC基準を満たした最初の提出物

2025年12月22日

最初の投稿 (実際)

2026年1月7日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月9日

QC基準を満たした最後の更新が送信されました

2026年11月6日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • IIT2025097

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。